Catherine Moukheibir - 03 Jul 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Reporting relationship: Director
Issuer ticker: MLTX
Reported as of: 03 Jul 2025
Net transaction value: -$1,146,565
SEC form: 4
Accepted by SEC: 07 Jul 2025, 16:03:16 UTC
Prior SEC filing: 12 Jun 2025
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir

Key filing fact

Catherine Moukheibir filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 07 Jul 2025.

Key facts

This page summarizes Catherine Moukheibir's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Jul 2025, 16:03.

Change

Previous filing in this sequence was filed on 12 Jun 2025.
Current net transaction value: -$1,146,565.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001772130 Primary reporting owner

Moukheibir Catherine

Relationship: Director
Address: C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir
Signature date: 07 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLTX transaction

Class A ordinary shares, par value $0.0001 per share

Options Exercise

Transaction value: $0
Shares: +23,500
Change %
Price: $0.000000
Shares after: 23,500
Date: 03 Jul 2025
Ownership: Direct

MLTX transaction

Class A ordinary shares, par value $0.0001 per share

Sale

Transaction value: $1,146,565
Shares: -23,500
Change %: -100%
Price: $48.79
Shares after: 0
Date: 03 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLTX transaction Derivative

Option to Buy

Options Exercise

Transaction value: $0
Shares: -23,500
Change %: -52%
Price: $0.000000
Shares after: 21,500
Date: 03 Jul 2025
Ownership: Direct
Underlying class: Class A ordinary shares, par value $0.0001 per share
Underlying amount: 23,500
Exercise price: $12.25
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $48.59 to $49.01. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F2

These options are fully vested.